Mendlein John

Director at FATE

Sold, on record
$1.1M
Dollars the filings state
Form 4 sales
2
Latest Jun 3, 2022
Form 144 notices
1
Proposed sales
Quarters with a sale
0 of the last 8
No sale in two years
Companies
1
Filed as an executive or holder

Companies

  • FATEFATE THERAPEUTICS INCDirector

Sales by reason

0
Routine
2
Plan not stated
0
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per year, every sale on record.

Sales chart range

Timeline

  1. Dec 29, 2025Notice

    FATE

    Filed a notice to sell 38,428 shares

    $39k38,428 shares

    Filed Dec 29, 2025Form 144

  2. Jun 3, 2022Plan not stated

    FATE

    Sold 0.9% of their holdings

    $31k1,364 shares at $22.79

    Filed Jun 6, 2022Form 4

  3. Mar 10, 2022Plan not stated

    FATE

    Sold 16.5% of their holdings

    $1.1M31,562 shares at $35.02

    Filed Mar 11, 2022Form 4

3 of 3

Every transaction

Every transaction on a Form 4 or Form 5 by Mendlein John
TradedFiledStockRoleWhatAmountPriceValueHeld afterSource
May 29, 2025May 30, 2025FATEDirectorAwardedStock Option (Right to Buy)55,00055,000SEC
Jun 20, 2024Jun 21, 2024OMGADirectorAwardedStock Option (Right to Buy)25,00025,000SEC
Jun 7, 2024Jun 11, 2024FATEDirectorAwardedStock Option (Right to Buy)40,00040,000SEC
Jun 7, 2023Jun 9, 2023OMGADirectorAwardedStock Option (Right to Buy)18,11818,118SEC
Jun 6, 2023Jun 7, 2023FATEDirectorAwardedStock Option (Right to Buy)40,00040,000SEC
Jan 19, 2023Jan 20, 2023FATEDirectorExercised or settledStock Option (Right to Buy)28,4610SEC
Jan 19, 2023Jan 20, 2023FATEDirectorExercised options28,461$1.37$39k311,231SEC
Jan 13, 2023Jan 13, 2023FATEDirectorBought124,679$5.60$698k282,770SEC
Jun 9, 2022Jun 13, 2022FATEDirectorAwardedStock Option (Right to Buy)11,89311,893SEC
Jun 9, 2022Jun 13, 2022FATEDirectorAwarded8,650166,741SEC
Jun 8, 2022Jun 10, 2022OMGADirectorAwardedOption (Right to Buy)18,11818,118SEC
Jun 3, 2022Jun 6, 2022FATEDirectorSold1,364$22.79$31k158,091SEC
Mar 10, 2022Mar 11, 2022FATEDirectorSold31,562$35.02$1.1M159,455SEC
Mar 10, 2022Mar 11, 2022FATEDirectorExercised or settledStock Option (Right to Buy)31,5620SEC
Mar 10, 2022Mar 11, 2022FATEDirectorExercised options31,562$1.63$51k191,017SEC
Jun 2, 2021Jun 4, 2021FATEDirectorAwardedStock Option (Right to Buy)4,3344,334SEC
Jun 2, 2021Jun 4, 2021FATEDirectorAwarded2,681159,455SEC
May 1, 2020May 5, 2020FATEDirectorAwardedStock Option (right to buy)16,00016,000SEC
May 8, 2019May 10, 2019ATYRDirectorAwardedStock Option (right to buy)20,00020,000SEC
May 3, 2019May 7, 2019FATEDirectorAwardedStock Option (right to buy)16,00016,000SEC
Dec 21, 2018Dec 26, 2018ATYRDirectorBought245,000$0.42$102k615,382SEC
May 15, 2018May 17, 2018ATYRDirectorAwardedStock Option (right to buy)20,00020,000SEC
May 2, 2018May 4, 2018FATEDirectorAwardedStock Option (right to buy)16,00016,000SEC
Jan 2, 2018Jan 2, 2018ATYRDirectorAwardedStock Option (right to buy)32,00032,000SEC
Aug 31, 2017Sep 5, 2017ATYRCEO and DirectorBoughtWarrant to Purchase Common Stock14,15114,151SEC
Aug 31, 2017Sep 5, 2017ATYRCEO and DirectorBought37,736$2.65$100k367,883SEC
Jun 15, 2017Jun 19, 2017EDITDirectorAwardedStock Option (right to buy)11,53811,538SEC
May 2, 2017May 4, 2017FATEDirectorAwardedStock Option (right to buy)25,00025,000SEC
Apr 24, 2017Apr 26, 2017ATYRCEO and DirectorBought124$3.00$372327,647SEC
Apr 20, 2017Apr 20, 2017ATYRCEO and DirectorBought2,552$3.00$8k327,523SEC
Feb 7, 2017Feb 9, 2017ATYRCEO and DirectorAwardedEmployee Stock Option (right to buy)185,000185,000SEC
Dec 19, 2016Dec 21, 2016ATYRCEO and DirectorBought69,000$2.20$152k324,971SEC
May 11, 2016May 13, 2016FATEDirectorAwardedStock Option (right to buy)25,00025,000SEC
Apr 5, 2016Apr 7, 2016ATYRCEO and DirectorBought2,500$3.52$9k250,971SEC
Apr 5, 2016Apr 6, 2016ATYRCEO and DirectorBought2,500$3.55$9k248,471SEC
Feb 3, 2016Feb 4, 2016EDITDirectorAwardedStock Option (right to buy)96,15396,153SEC
Jan 27, 2016Jan 29, 2016ATYRCEO and DirectorAwardedEmployee Stock Option (right to buy)135,000135,000SEC
Jan 4, 2016Jan 6, 2016ATYRCEO and DirectorAwardedEmployee Stock Option (right to buy)148,732148,732SEC
Oct 1, 2015Oct 5, 2015ATYROfficer, DirectorAwardedEmployee Stock Option (right to buy)136,07065,070SEC
May 13, 2015May 15, 2015FATEDirectorAwardedStock Option (right to buy10,00010,000SEC
May 12, 2015May 14, 2015ATYRCEO and Executive ChairmanConvertedSeries C Redeemable Convertible Preferred Stock191,3400SEC
May 12, 2015May 14, 2015ATYRCEO and Executive ChairmanConverted24,055245,971SEC
May 6, 2015May 8, 2015ATYRCEO & Executive CharimanAwardedStock Option (right to buy)163,437163,437SEC
Jun 6, 2014Jun 9, 2014FATEDirectorAwardedStock Option (right to buy)10,00010,000SEC
Oct 4, 2013Oct 7, 2013FATEDirectorBought16,667$6.00$100k156,774SEC
Jan 16, 2009Jan 21, 2009Monogram Biosciences, Inc.DirectorAwardedStock Option (Rt to Buy)3,5003,500SEC
Mar 13, 2008Mar 17, 2008Monogram Biosciences, Inc.DirectorAwardedStock Option (Rt to Buy)20,00020,000SEC
Mar 29, 2007Apr 13, 2007Monogram Biosciences, Inc.DirectorAwardedStock Option (Right to Buy)20,00020,000SEC
Apr 7, 2006Apr 11, 2006Monogram Biosciences, Inc.DirectorAwardedStock Option (Right to Buy)20,00020,000SEC

Sales and notices (3)

Form 144 notices and Form 4 sales by Mendlein John
Source
Dec 29, 2025Dec 29, 2025FATEDirectorForm 144 notice38,428$39kNoticeSEC
Jun 3, 2022Jun 6, 2022FATEDirectorForm 4 sale1,364$31k0.9%Plan not statedSEC
Mar 10, 2022Mar 11, 2022FATEDirectorForm 4 sale31,562$1.1M16.5%Plan not statedSEC